Flash FinanceUS
After hours S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Contineum Therapeutics, Inc. (CTNM)

Contineum Therapeutics' MOONLIGHT-1 depression trial misses primary efficacy endpoint

Negative Impact 4 of 5 product/contract Written later

Contineum Therapeutics reported that the Phase 2 MOONLIGHT-1 trial of JNJ-5120/PIPE-307 in major depressive disorder did not achieve its primary efficacy endpoint. Johnson & Johnson, which develops the drug under a global license and development agreement, is still evaluating the data, including prespecified exploratory endpoints, to decide next steps.

Key points

  • Trial did not meet its primary efficacy endpoint, measured as change from baseline in MADRS total score at Day 5 versus placebo.
  • JNJ-5120/PIPE-307 was well-tolerated with no new safety signals.
  • Johnson & Johnson continues to assess the totality and clinical relevance of the findings to inform next steps for the drug.
  • Analyses of the data, including prespecified exploratory endpoints, are ongoing.

The filing

CompanyContineum Therapeutics, Inc. (CTNM)
Form8-K, current report
Filed with the SECSep 14, 2026, 4:07 PM ET
Accession number0001628280-26-061834

Items reported: 8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:44 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on September 14, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.